{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:21:08Z","timestamp":1787966468348,"version":"build-2784847793"},"reference-count":29,"publisher":"AOSIS","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PHCFM"],"DOI":"10.4102\/phcfm.v17i1.5096","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:35:55Z","timestamp":1757504155000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Low metformin concentrations in obese people with HIV treated with dolutegravir"],"prefix":"10.4102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6464-4257","authenticated-orcid":false,"given":"Roland","family":"van Rensburg","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1815-5150","authenticated-orcid":false,"given":"Eric H.","family":"Decloedt","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05bk57929","id-type":"ROR","asserted-by":"publisher"}],"name":"Stellenbosch University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Trickey A, Sabin CA, Burkholder G, et al. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: A collaborative analysis of cohort studies. Lancet HIV. 2023;10(5):e295\u2013e307. https:\/\/doi.org\/10.1016\/S2352-3018(23)00028-0","DOI":"10.1016\/S2352-3018(23)00028-0"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bailin SS, Gabriel CL, Wanjalla CN, et al. Obesity and weight gain in persons with HIV. Curr HIV\/AIDS Rep. 2020;17(2):138\u2013150. https:\/\/doi.org\/10.1007\/s11904-020-00483-5","DOI":"10.1007\/s11904-020-00483-5"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Moyo-Chilufya M, Maluleke K, Kgarosi K, et al. The burden of non-communicable diseases among people living with HIV in Sub-Saharan Africa: A systematic review and meta-analysis. eClinicalMedicine. 2023;65:102255. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102255","DOI":"10.1016\/j.eclinm.2023.102255"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Gizamba JM, Davies J, Africa C, et al. Prevalence of obesity, hypertension and diabetes among people living with HIV in South Africa: A systematic review and meta-analysis. BMC Infect Dis. 2023;23(1):1\u201320. https:\/\/doi.org\/10.1186\/s12879-023-08736-5","DOI":"10.1186\/s12879-023-08736-5"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71(6):1379\u20131389. https:\/\/doi.org\/10.1093\/cid\/ciz999","DOI":"10.1093\/cid\/ciz999"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Herrin M, Tate JP, Akg\u00fcn KM, et al. Weight gain and incident diabetes among HIV-infected veterans initiating antiretroviral therapy compared with uninfected individuals. J Acquir Immune Defic Syndr. 2016;73(2):228\u2013236. https:\/\/doi.org\/10.1097\/QAI.0000000000001071","DOI":"10.1097\/QAI.0000000000001071"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Asgedom YS, Kebede TM, Gebrekidan AY, et al. Prevalence of metabolic syndrome among people living with human immunodeficiency virus in sub-Saharan Africa: A systematic review and meta-analysis. Sci Rep. 2024;14(1):1\u201314. https:\/\/doi.org\/10.1038\/s41598-024-62497-y","DOI":"10.1038\/s41598-024-62497-y"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Boake M, Mash R. Diabetes in the Western Cape, South Africa: A secondary analysis of the diabetes cascade database 2015\u20132020. Primary Care Diabetes. 2022;16(4):555\u2013561. https:\/\/doi.org\/10.1016\/j.pcd.2022.05.011","DOI":"10.1016\/j.pcd.2022.05.011"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Pillay S, Mahomed F, Aldous C. A deadly combination-HIV and diabetes mellitus: Where are we now? S Afr Med J. 2016;106(4):378\u2013383. https:\/\/doi.org\/10.7196\/SAMJ.2016.v106i4.9950","DOI":"10.7196\/SAMJ.2016.v106i4.9950"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Solini A, Tric\u00f2 D. Clinical efficacy and cost-effectiveness of metformin in different patient populations: A narrative review of real-world evidence. Diabetes Obes Metab. 2024;26(S3):20\u201330. https:\/\/doi.org\/10.1111\/dom.15729","DOI":"10.1111\/dom.15729"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nansseu JR, Bigna JJ, Kaze AD, et al. Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy. Epidemiology. 2018;29(3):431\u2013441. https:\/\/doi.org\/10.1097\/EDE.0000000000000815","DOI":"10.1097\/EDE.0000000000000815"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Grundlingh N, Zewotir TT, Roberts DJ, et al. Assessment of prevalence and risk factors of diabetes and pre-diabetes in South Africa. J Health Popul Nutr. 2022;41(1):1\u201312. https:\/\/doi.org\/10.1186\/s41043-022-00281-2","DOI":"10.1186\/s41043-022-00281-2"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Magodoro IM, Okello S, Dungeni M, et al. Association between HIV and prevalent hypertension and diabetes mellitus in South Africa: Analysis of a nationally representative cross-sectional survey. Int J Infect Dis. 2022;121:217\u2013225. https:\/\/doi.org\/10.1016\/j.ijid.2022.05.035","DOI":"10.1016\/j.ijid.2022.05.035"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016;72(4):400\u2013407. https:\/\/doi.org\/10.1097\/QAI.0000000000000983","DOI":"10.1097\/QAI.0000000000000983"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Wang ZJ, Yin OQP, Tomlinson B, et al. OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine. Pharmacogenet Genomics. 2008;18(7):637\u2013645. https:\/\/doi.org\/10.1097\/FPC.0b013e328302cd41","DOI":"10.1097\/FPC.0b013e328302cd41"},{"key":"ref15","unstructured":"M\u00e9decins Sans Fronti\u00e8res. MSF medical guidelines: Dolutegravir (DTG oral) [homepage on the Internet]. cited 2024 Aug 13. Available from: https:\/\/medicalguidelines.msf.org\/en\/viewport\/EssDr\/english\/dolutegravir-dtg-oral-38537537.html"},{"key":"ref16","unstructured":"Liverpool HIV Interactions. Dolutegravir (DTG)-metformin [homepage on the Internet]. [cited 2024 Aug 13]. Available from: https:\/\/www.hiv-druginteractions.org\/interactions\/81694"},{"key":"ref17","unstructured":"Simbayi LC, Zuma K, Zungu N, et al. South African national HIV prevalence, incidence, behaviour and communication survey, 2017. Cape Town: HSRC Press; 2019."},{"key":"ref18","unstructured":"Country factsheet \u2013 South Africa. UNAIDS 2023 estimates [homepage on the Internet]. [cited 2024 Dec 19]. Available from: https:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"van Rensburg R, Kellermann T, Pillay-Fuentes Lorente V, et al. Reduced metformin concentrations in obese women with HIV treated with dolutegravir. J Infect Dis. 2025:jiaf305.","DOI":"10.1093\/infdis\/jiaf305"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Berton M, Bettonte S, Stader F, et al. Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models. Clin Pharmacokinet 2022;61(9):1251.","DOI":"10.1007\/s40262-022-01132-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Van Rongen A, Van der Aa MP, Matic M, et al. Increased metformin clearance in overweight and obese adolescents: A pharmacokinetic substudy of a randomized controlled trial. Paediatr Drugs. 2018;20(4):365. https:\/\/doi.org\/10.1007\/s40272-018-0293-1","DOI":"10.1007\/s40272-018-0293-1"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Bardin C, Nobecourt E, Larger E, et al. Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus. Eur J Clin Pharmacol. 2012;68(6):961\u2013968. https:\/\/doi.org\/10.1007\/s00228-011-1207-0","DOI":"10.1007\/s00228-011-1207-0"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Zhang J, Hayes S, Sadler BM, et al. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients. Br J Clin Pharmacol. 2015;80(3):502\u2013514. https:\/\/doi.org\/10.1111\/bcp.12639","DOI":"10.1111\/bcp.12639"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Cattaneo D, Resnati C, Rizzardini G, et al. Dolutegravir and metformin: A clinically relevant or just a pharmacokinetic interaction? AIDS. 2018;32:532\u2013533. https:\/\/doi.org\/10.1097\/QAD.0000000000001720","DOI":"10.1097\/QAD.0000000000001720"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Gervasoni C, Minisci D, Clementi E, et al. How relevant is the interaction between dolutegravir and metformin in real life? J Acquir Immune Defic Syndr. 2017;75:e24\u2013e26. https:\/\/doi.org\/10.1097\/QAI.0000000000001292","DOI":"10.1097\/QAI.0000000000001292"},{"key":"ref26","unstructured":"Dawson E, Brehaut J, Giguere P. National survey assessing knowledge and management of the drug interaction between dolutegravir and metformin by Canadian HIV practitioners [homepage on the Internet]. 2017 [cited 2025 Jun 20]. Available from: https:\/\/tspace.library.utoronto.ca\/handle\/1807\/80571."},{"key":"ref27","unstructured":"South African National Department of Health Standard Treatment Guidelines, Hospital Level, Adults. Chapter 10: HIV and AIDS [homepage on the Internet]. [cited 2025 Jun 12] Available from: https:\/\/www.health.gov.za\/wp-content\/uploads\/2024\/12\/Adult-Hospital-Chapter-10-HIV-and-AIDS-with-supporting-NEMLC-report-and-reviews-2020-4-Version-2.1-9-December-2024.pdf"},{"key":"ref28","unstructured":"Liverpool HIV Interactions. Dolutegravir (DTG)-metformin [homepage on the Internet]. [cited 2025 Jun 12]. Available from: https:\/\/www.hiv-druginteractions.org\/interactions\/81694"}],"container-title":["African Journal of Primary Health Care & Family Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:36:03Z","timestamp":1757504163000},"score":1,"resource":{"primary":{"URL":"https:\/\/phcfm.org\/index.php\/phcfm\/article\/view\/5096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":29,"URL":"https:\/\/doi.org\/10.4102\/phcfm.v17i1.5096","relation":{},"ISSN":["2071-2928","2071-2936"],"issn-type":[{"value":"2071-2928","type":"print"},{"value":"2071-2936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"a5096"}}